Terminology Service for NFDI4Health
JSON

Lexatumumab

Go to external page http://purl.obolibrary.org/obo/NCIT_C64621

A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types. [ ]

Term info

Label

Lexatumumab

Synonyms
  • Anti-TRAIL Receptor 2 Monoclonal Antibody HGS-ETR2
  • HGS-ETR2
  • HGS1018
  • LEXATUMUMAB
  • Lexatumumab
  • Monoclonal Antibody HGS-ETR2
  • anti-TRAIL R2 mAb HGS-ETR2
  • lexatumumab
Subsets

NCIT_C128784, NCIT_C63923, NCIT_C157711, NCIT_C157712

ALT DEFINITION

A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL-R2 on the surface of some tumor cells, which may kill the tumor cells. HGS-ETR2 is a type of monoclonal antibody.

CAS Registry

845816-02-6

FDA UNII Code

967Q0SJD77

Has Target

http://purl.obolibrary.org/obo/NCIT_C18178

Legacy Concept Name

Lexatumumab

Preferred Name

Lexatumumab

Semantic Type

Pharmacologic Substance, Amino Acid, Peptide, or Protein, Immunologic Factor

UMLS CUI

C1721684

code

C64621